Development of a Therapeutic Education Program for Patients With Metastatic Prostate Cancer Treated With New Generation Hormone Therapy

Development of a Therapeutic Education Program for Patients With Metastatic Prostate Cancer Treated With New Generation Hormone Therapy: Construction and Feasibility Study

The development of a personalized therapeutic education program dedicated to patients with metastatic prostate cancer and receiving next-generation hormone therapy would improve their knowledge of the disease, medication adherence and quality of life.

Inclusion Criteria:

• Patients with metastatic prostate cancer treated with enzalutamide or abiraterone acetate for at least 3 months
• The patient must have given their free and informed consent and signed the consent form
• The patient must be insured or the beneficiary of an insurance policy

Exclusion Criteria:

• The subject is not in a fit state to express their consent
• It is impossible to give the subject informed information
• The patient is under safeguard of justice or state guardianship